Abstract: A method for controlling charging of a power source of a hybrid vehicle. The method includes determining a maximum output level of a primary power source, determining a state of charge of a secondary power source, determining a charge torque modifier value based on the maximum output torque level and the state of charge, determining a target torque level for an electrical machine based on the charge torque modifier value, and driving the electrical machine at the target torque level with the primary power source to charge the secondary power source.

Abstract: A gaseous fuel management system for an automotive vehicle includes at least one gas sensor for detecting the presence of gaseous fuel outside of the confines of the vehicle's fuel storage tank, fuel lines, and prime mover. In the event that fugitive gas is detected and the concentration exceeds a predetermined threshold, the fuel supply to the vehicle's prime mover will be shut off and, if so equipped, the vehicle may then be operated in a battery power mode for the convenience of the driver.

Abstract: A method for controlling charging of a power source of a hybrid vehicle. The method includes determining a maximum output level of a primary power source, determining a state of charge of a secondary power source, determining a charge torque modifier value based on the maximum output torque level and the state of charge, determining a target torque level for an electrical machine based on the charge torque modifier value, and driving the electrical machine at the target torque level with the primary power source to charge the secondary power source.

Abstract: This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.

Abstract: This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.

Abstract: This invention provides a composition, device and method for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood.